The efficacy of pemetrexed as a third- or fourth-line therapy and the significance of thymidylate synthase expression in patients with advanced non-small cell lung cancer

Lung Cancer

Volumn 69, Issue 3, 2010, Pages 323-329

  Chang, Myung Hee ^a   Ahn, Jin Seok ^a   Lee, Jeeyun ^a   Kim, Kyoung Ha ^a   Park, Yeon Hee ^a   Han, Joungho ^a   Ahn, Myung Ju ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Non small cell lung cancer; Pemetrexed; Predictors; Prognostic factors; Thymidylate synthase

Indexed keywords

CYANOCOBALAMIN; DEXAMETHASONE; ERLOTINIB; FOLIC ACID; GEFITINIB; PEMETREXED; PLATINUM; THYMIDYLATE SYNTHASE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER SURVIVAL; CONSTIPATION; DEATH; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; FACE EDEMA; FATIGUE; FEMALE; GENERALIZED EDEMA; HEADACHE; HERPES ZOSTER; HUMAN; INDIGESTION; INFECTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; PRURITUS; RASH; SEX DIFFERENCE; SIDE EFFECT; SMOKING;

EID: 77955097228     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.12.002     Document Type: Article

References (24)

1. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002, 346:92-98.
2. Shepherd F.A., Dancey J., Ramlau R., Mattson K., Gralla R., O'Rourke M., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000, 18:2095-2103.
3. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
4. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
5. Ng R., Loreto M., Lee R., Leighl N.B. Brief report: retrospective review of efficacy of erlotinib or gefitinib compared to docetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy. Lung Cancer 2008, 61:262-265.
6. Melosky B., Agulnik J., Assi H. Retrospective practice review of treatment of metastatic non-small-cell lung cancer with second-line erlotinib. Curr Oncol 2008, 15:279-285.
7. Bearz A., Garassino I., Cavina R., Favaretto A., Boccalon M., Talamini R., et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 2008, 60:240-245.
8. Shih C., Chen V.J., Gossett L.S., Gates S.B., MacKellar W.C., Habeck L.L., et al. LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997, 57:1116-1123.
9. Huang C.L., Yokomise H., Kobayashi S., Fukushima M., Hitomi S., Wada H. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. Int J Oncol 2000, 17:47-54.
10. Nakagawa T., Tanaka F., Otake Y., Yanagihara K., Miyahara R., Matsuoka K., et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002, 35:165-170.
11. Ceppi P., Volante M., Saviozzi S., Rapa I., Novello S., Cambieri A., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006, 107:1589-1596.
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
13. Sun J.M., Lee K.W., Kim J.H., Kim Y.J., Yoon H.I., Lee J.H., et al. Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer. Jpn J Clin Oncol 2009, 39:27-32.
14. Ailawadhi S., Derby L., Natarajan R., Fetterly G., Reid M., Ramnath N. Erlotinib for metastatic non-small-cell lung cancer: first-, second- or third-line setting - does it matter? A single-institution experience. Oncology 2009, 76:85-90.
15. Itaya T., Yamaoto N., Ando M., Ebisawa M., Nakamura Y., Murakami H., et al. Influence of histological type, smoking history and chemotherapy on survival after first-line therapy in patients with advanced non-small cell lung cancer. Cancer Sci 2007, 98:226-230.
16. Scagliotti G.V., Parikh P., von Pawel J., Biesma B., Vansteenkiste J., Manegold C., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008, 26:3543-3551.
17. Pirker R., Pereira J.R., Szczesna A., von Pawel J., Krzakowski M., Ramlau R., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
18. Lee H.Y., Ahn M.J., Park Y.H., Ahn J.S., Kim B.S., Kim H.K., et al. Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: a prospective, multicenter trial. Lung Cancer 2009, 66(3):338-343. Epub 2009 Mar 18.
19. Miyoshi T., Kondo K., Toba H., Yoshida M., Fujino H., Kenzaki K., et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase expression in tumor tissue, regarding the efficacy of postoperatively administered UFT (tegafur+uracil) in patients with non-small cell lung cancer. Anticancer Res 2007, 27:2641-2648.
20. Huang C., Liu D., Masuya D., Nakashima T., Kameyama K., Ishikawa S., et al. Clinical application of biological markers for treatments of resectable non-small-cell lung cancers. Br J Cancer 2005, 92:1231-1239.
21. Otake Y., Tanaka F., Yanagihara K., Hitomi S., Okabe H., Fukushima M., et al. Expression of thymidylate synthase in human non-small cell lung cancer. Jpn J Cancer Res 1999, 90:1248-1253.
22. Inoue K., Takao M., Watanabe F., Tarukawa T., Shimamoto A., Kaneda M., et al. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer-in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Lung Cancer 2005, 49:47-54.
23. Chen G., Gharib T.G., Huang C.C., Taylor J.M., Misek D.E., Kardia S.L., et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002, 1:304-313.
24. Hashimoto H., Ozeki Y., Sato M., Obara K., Matsutani N., Nakagishi Y., et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006, 106:1595-1601.